Thermo Fisher Scientific has signed an agreement with Mainz Biomed to develop and launch a next-generation colorectal cancer ...

The demand for organoids is being driven mainly by an increased preference for personalized medicine, a rising trend of using organoids as alternatives to animal testing, and their expanding ...

Growth was driven by our focus on the Reach product through re-engineering and expanded sales efforts, leading to the addition of 1,785 customers through October 2024. In total, we now serve nearly ...